시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
단클론항체 시장 규모, 점유율, 예측 및 동향 분석 : 제품 유형, 용도, 공급원, 생산 및 최종 사용자별 - 세계 예측(-2031년)
Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type Application, Source, Production, End User - Global Forecast to 2031
상품코드 : 1504160
리서치사 : Meticulous Market Research Pvt. Ltd.
발행일 : On Demand Report
페이지 정보 : 영문 410 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,175 ￦ 5,749,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회만 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 5,875 ￦ 8,091,000
PDF (Multi User License) help
PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,875 ￦ 10,845,000
PDF (Global Site License) help
PDF 보고서를 동일 기업 및 자회사의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계 단클론항체 시장은 2024-2031년간 11.2%의 연평균 복합 성장률(CAGR)로 2031년까지 4,498억 8,000만 달러에 달할 것으로 예측됩니다.

이 보고서는 광범위한 2차 및 1차 연구와 단클론항체 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 억제요인, 도전 과제 및 기회 분석으로 구성되어 있습니다. 단클론항체 시장의 성장은 전 세계 암 및 자가 면역 질환의 높은 부담, 임상시험 및 연구 자금 조달 증가, 바이오 제약 산업의 성장, 감염성 질환의 유병률 증가, 단백질체학 및 유전체학 연구 증가에 의해 주도되고 있습니다. 그러나 대체 진단 검사의 가용성, 항체 개발에 소요되는 높은 비용과 시간이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

또한, 제약 및 생명공학 기업의 R&D 투자 증가, 임상시험 및 의학 연구에서의 항체 적용 확대, 신흥국에서의 연구 활동 증가, 새로운 바이오마커 식별에 대한 수요 증가, 진단 검사 강화를 위한 노력 등이 시장 성장의 기회를 창출할 것으로 예상됩니다. 시장 성장 기회를 창출할 것으로 예상됩니다. 그러나 항체 검사의 낮은 정확도, 높은 제조 비용, 연구용 항체의 품질 및 안정성 문제, 제조 공정의 복잡성 등이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 인사이트

제5장 단클론항체 시장 : 유형별 평가

제6장 단클론항체 시장 : 제조 공정별 평가

제7장 단클론항체 시장 : 공급원별 평가

제8장 단클론항체 시장 : 최종사용자별 평가

제9장 단클론항체 시장 : 지역별 평가

제10장 경쟁 분석

제11장 기업 개요(기업 개요, 재무 개요, 제품 포트폴리오, 전략적 전개, SWOT 분석)

(주 : 주요 5개사의 SWOT 분석을 게재)

제12장 부록

LSH
영문 목차

영문목차

Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User-Global Forecast to 2031

The global monoclonal antibodies market is projected to reach $449.8 billion by 2031 at a CAGR of 11.2% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the monoclonal antibodies market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the monoclonal antibodies market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics. However, the availability of alternative diagnostic tests and the high costs & time required for antibody development restrain the market's growth.

Furthermore, increasing R&D investments by pharmaceutical & biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities. However, the inaccuracy of antibody tests, high manufacturing costs, concerns regarding the quality & stability of research antibodies, and complexities in the production process are some of the challenges impeding the market's growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Among the types covered in this report, in 2024, the therapeutic monoclonal antibodies segment is expected to account for the largest share of over 90.2% of the monoclonal antibodies market. The therapeutic monoclonal antibodies segment is further sub-segmented into oncology, autoimmune diseases, neurological diseases, infectious diseases, and other therapeutic areas. The large market share of this segment is attributed to the increasing approvals for the therapeutical monoclonal antibodies, rising demand for biosimilars, increasing prevalence of target disease, technological advancements in the formulation of antibodies, an increasing number of pipeline products, and fewer side effects of monoclonal antibodies. Additionally, with the increasing prevalence of cancer, the demand for monoclonal antibodies is also increasing for personalized cancer therapies. According to GLOBOCAN, the prevalence of cancer is expected to increase by 63.4% in 2045 from 2022.

Among the production processes covered in this report, in 2024, the in vitro process segment is expected to account for the largest share of the monoclonal antibodies market. The in vitro segment is further segmented into upstream process and downstream process. The in vitro process scales up antibody production without reliance on animal models and animal testing. It increases the production of MABs and also mitigates the ethical concerns associated with the use of animals, thus preferred over the in vivo process.

Among the sources covered in this report, in 2024, the human segment is expected to account for the largest share of the monoclonal antibodies market. Human sources are preferred for the production of monoclonal antibodies to increase treatment efficiency by reducing the risk of immunogenicity or adverse immune response. Key players are also using human sources for the development of monoclonal antibodies to improve the safety profile of MABs, production of stable human hybridomas, and ease of scaling up production.

Among the end users covered in this report, the hospitals segment is expected to account for the largest share of the monoclonal antibodies market. The large market share of this segment is attributed to the availability of MAB therapies in hospitals, the increasing number of hospitals in emerging economies, and the launch of dedicated monoclonal antibody facilities by hospitals.

An in-depth analysis of the geographical scenario of the global monoclonal antibodies market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.

In 2024, North America is expected to account for the largest share of over 34.9% of the monoclonal antibodies market. The largest share of the regional market is attributed to the presence of key players, availability of advanced antibody engineering technology, rising number of approvals, and supportive government initiatives for the development and use of monoclonal antibodies. For instance, in September 2023, the U.S. Department of Health and Human Services announced an initiative to give underinsured and uninsured Americans access to the COVID-19 monoclonal antibody treatment bebtelovimab even after the product availability in the commercial market.

Scope of the Report:

Monoclonal Antibodies Market Assessment-by Type

Note: 1) Other Research Areas include Ophthalmology and Rare Diseases

2) Other Research Technologies include electrophoretic mobility shift assay (EMSA) and enzyme-linked immunospot (ELISPOT) assay

3) Other Diagnostic Applications include Alzheimer's, autoimmune diseases, cardiac diseases, and diabetes.

4) Other Diagnostic Technologies include Immunofluorescence, flow cytometry, in situ hybridization, dot blot, and radioimmunoassay.

5) Other Therapeutic Areas include cardiac diseases, diabetes, ophthalmology, and hematology

Monoclonal Antibodies Market Assessment-by Production Process

Monoclonal Antibodies Market Assessment-by Source

Note: Other Sources include goat, sheep, chicken, and llama

Monoclonal Antibodies Market Assessment-by End User

Note: Other End Users include academic & research institutes, nursing centers, and long-term care centers

Monoclonal Antibodies Market Assessment-by Geography

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

5. Monoclonal Antibodies Market Assessment-by Type

6. Monoclonal Antibodies Market Assessment-by Production Process

7. Monoclonal Antibodies Market Assessment-by Source

8. Monoclonal Antibodies Market Assessment-by End User

9. Monoclonal Antibodies Market Assessment-by Geography

10. Competition Analysis

11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)

(Note: SWOT analysis of the top 5 companies will be provided.)

12. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기